Evidence map›Paper›PMID 41435220›Full record

ArticleNeurology(R) neuroimmunology & neuroinflammation2026

Progression Independent of Relapse Activity in Aquaporin-4-IgG-Positive NMOSD: A Decade-Long Cohort Study.

You-Ri Kang, Ki Hoon Kim, Jae-Won Hyun, Su-Hyun Kim, Ho Jin Kim

Abstract read
In one paragraph

Article in Neurology(R) neuroimmunology & neuroinflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

You-Ri KangDepartment of Neurology, Research Institute and Hospital of National Cancer Center, Goyang, Korea.ORCID 0000-0001-5189-1323
Ki Hoon KimDepartment of Neurology, Research Institute and Hospital of National Cancer Center, Goyang, Korea.ORCID 0000-0001-6428-061X
Jae-Won HyunDepartment of Neurology, Research Institute and Hospital of National Cancer Center, Goyang, Korea.ORCID 0000-0003-0288-771X
Su-Hyun KimDepartment of Neurology, Research Institute and Hospital of National Cancer Center, Goyang, Korea.ORCID 0000-0002-0679-0918
Ho Jin KimDepartment of Neurology, Research Institute and Hospital of National Cancer Center, Goyang, Korea.ORCID 0000-0002-8672-8419

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesDisability in neuromyelitis optica spectrum disorder (NMOSD) is traditionally considered relapse-driven, but recent studies have suggested possible subclinical progression. Whether this translates into clinically meaningful disability worsening remains unclear, and quantitative data on progression independent of relapse activity (PIRA) in NMOSD are limited. We investigated the frequency and clinical relevance of PIRA in a large cohort with long-term follow-up.

methodsWe retrospectively analyzed 281 patients with AQP4-IgG-positive NMOSD with ≥2 years of follow-up. Significant Expanded Disability Status Scale (EDSS) worsening occurred following conventional thresholds, using a roving baseline. PIRA was defined as EDSS worsening without relapse between assessments, confirmed ≥6 months later, sustained, and not attributable to confounders. Relapse-associated worsening (RAW) was defined when the best EDSS score assessed ≥6 months after relapse still met the threshold.

resultsThe mean follow-up duration was 11.3 ± 5.1 years, and the mean relapse-free duration was 8.3 ± 5.2 years. A total of 1,662 EDSS assessments were performed, with a median of 5 per patient (interquartile range, 4-7). Seven patients (2.5%) met PIRA criteria. Despite no treatment escalation, none worsened further. Among 194 patients with relapses, 70 (36.1%) experienced RAW. DISCUSSION: PIRA was rare, even with extended observation using a formal framework, reaffirming relapse as the principal driver of disability and supporting continued focus on relapse prevention.

Indexed as

Aquaporin 4AutoantibodiesDisease ProgressionImmunoglobulin GNeuromyelitis OpticaAdultAgedCohort StudiesFemaleFollow-Up StudiesHumansMaleMiddle AgedRecurrenceRetrospective StudiesAQP4 protein, humanAquaporin 4AutoantibodiesImmunoglobulin G

Identifiers

PMID41435220
PMCPMC12735300

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.